178 related articles for article (PubMed ID: 19543143)
1. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom.
Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ
Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
3. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
5. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
6. Determining the cost of genital warts: a study from Ireland.
Dee A; Howell F; O'Connor C; Cremin S; Hunter K
Sex Transm Infect; 2009 Sep; 85(5):402-3. PubMed ID: 19004863
[TBL] [Abstract][Full Text] [Related]
7. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
8. [Genital warts and HPV vaccination].
Pilka R; Dvorák V; Fait T
Ceska Gynekol; 2011 Dec; 76(6):468-70. PubMed ID: 22312844
[TBL] [Abstract][Full Text] [Related]
9. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
10. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
11. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.
Jit M; Chapman R; Hughes O; Choi YH
BMJ; 2011 Sep; 343():d5775. PubMed ID: 21951758
[TBL] [Abstract][Full Text] [Related]
12. Trends in Male and Female Genital Warts Among Adolescents in a Safety-Net Health Care System 2004-2013: Correlation With Introduction of Female and Male Human Papillomavirus Vaccination.
Perkins RB; Legler A; Hanchate A
Sex Transm Dis; 2015 Dec; 42(12):665-8. PubMed ID: 26562694
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
14. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
15. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
Ali H; Donovan B; Wand H; Read TR; Regan DG; Grulich AE; Fairley CK; Guy RJ
BMJ; 2013 Apr; 346():f2032. PubMed ID: 23599298
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
17. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Hoy T; Singhal PK; Willey VJ; Insinga RP
Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
[TBL] [Abstract][Full Text] [Related]
18. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme.
Chow EP; Read TR; Wigan R; Donovan B; Chen MY; Bradshaw CS; Fairley CK
Sex Transm Infect; 2015 May; 91(3):214-9. PubMed ID: 25305210
[TBL] [Abstract][Full Text] [Related]
19. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
20. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France].
Monsonégo J; Breugelmans JG; Bouée S; Lafuma A; Bénard S; Rémy V
Gynecol Obstet Fertil; 2007 Feb; 35(2):107-13. PubMed ID: 17270482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
